{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:36:18Z","timestamp":1794454578653,"version":"4.9.1"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"name":"Foundation for Women and Girls with Blood Disorders","id":[{"id":"https:\/\/ror.org\/035f1yf77","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Center for Clinical and Translational Science, University of Utah","id":[{"id":"https:\/\/ror.org\/03r0ha626","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","award":["K12HD085816"],"award-info":[{"award-number":["K12HD085816"]}],"id":[{"id":"https:\/\/ror.org\/04byxyr05","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","award":["5K23HD112591"],"award-info":[{"award-number":["5K23HD112591"]}],"id":[{"id":"https:\/\/ror.org\/04byxyr05","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Center for Advancing Translational Sciences","award":["UM1 TR004409"],"award-info":[{"award-number":["UM1 TR004409"]}],"id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Direct oral anticoagulants are increasingly used for postoperative thromboprophylaxis, but use is limited in postpartum populations in the absence of data informing transfer into human milk. We evaluated the excretion of prophylactic-dose rivaroxaban into the milk of 20 low-risk lactating individuals from April through September 2024. Participants received two doses of prophylactic-dose rivaroxaban and provided blood and milk samples, with rivaroxaban concentrations quantified by liquid chromatography\u2013tandem mass spectrometry. Pharmacokinetic metrics were evaluated, and the relative infant dose was calculated. Maternal plasma and milk rivaroxaban concentration peaked 2 hours after the second dose. At maximum maternal milk concentration of rivaroxaban, the relative infant dose was 2.9%, below the 10% safety threshold for drug use during breastfeeding. Findings suggest that neonatal exposure is likely low risk for use of prophylactic-dose rivaroxaban in lactating individuals.<\/jats:p>","DOI":"10.1097\/aog.0000000000006153","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T22:00:55Z","timestamp":1766095255000},"page":"e116-e119","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Prophylactic-Dose Rivaroxaban Transfer Into Human Milk"],"prefix":"10.1097","volume":"147","author":[{"given":"Ann M.","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Job","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Rower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda A.","family":"Allshouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin K.","family":"Zinkhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Y.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie H.","family":"Shakib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome J.","family":"Federspiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torri D.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Ware","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"R1-20261111","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/AOG.0000000000002706","article-title":"Thromboembolism in pregnancy. ACOG Practice Bulletin No. 196. American College of Obstetricians and Gynecologists","volume":"132","year":"2018","journal-title":"Obstet Gynecol"},{"key":"R2-20261111","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2018.11.020","article-title":"Women's views, adherence and experience with postnatal thromboprophylaxis","volume":"173","author":"Guimicheva","year":"2019","journal-title":"Thromb Res"},{"key":"R3-20261111","doi-asserted-by":"crossref","first-page":"e207410","DOI":"10.1001\/jamanetworkopen.2020.7410","article-title":"Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial","volume":"3","author":"Guntupalli","year":"2020","journal-title":"JAMA Netw Open"},{"key":"R4-20261111","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20261111","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamasurg.2018.0374","article-title":"What surgeons should know about non-vitamin K oral anticoagulants: a review","volume":"153","author":"Verma","year":"2018","journal-title":"JAMA Surg"},{"key":"R6-20261111","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1712746","article-title":"Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty","volume":"378","author":"Anderson","year":"2018","journal-title":"N Engl J Med"},{"key":"R7-20261111","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/GRF.0000000000000740","article-title":"Novel antithrombotic agents in pregnancy anticoagulants and antiplatelet agents","volume":"66","author":"James","year":"2023","journal-title":"Clin Obstet Gynecol"},{"key":"R8-20261111","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/AOG.0000000000004388","article-title":"Transfer of apixaban into human milk","volume":"137","author":"Datta","year":"2021","journal-title":"Obstet Gynecol"},{"key":"R9-20261111","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00228-021-03154-5","article-title":"Direct oral anticoagulant safety during breastfeeding: a narrative review","volume":"77","author":"Daei","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"R10-20261111","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/bfm.2019.0124","article-title":"Rivaroxaban treatment in two breastfeeding mothers: a case series","volume":"15","author":"Muysson","year":"2020","journal-title":"Breastfeed Med"},{"key":"R11-20261111","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.chest.2016.01.021","article-title":"The direct factor Xa inhibitor rivaroxaban passes into human breast milk","volume":"150","author":"Wiesen","year":"2016","journal-title":"Chest"},{"key":"R12-20261111","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1089\/bfm.2019.0230","article-title":"Rivaroxaban concentration in breast milk during breastfeeding: a case study","volume":"14","author":"Saito","year":"2019","journal-title":"Breastfeed Med"},{"key":"R13-20261111","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2020006231","article-title":"Are apixaban and rivaroxaban distributed into human breast milk to clinically relevant concentrations?","volume":"136","author":"Zhao","year":"2020","journal-title":"Blood"},{"key":"R14-20261111","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMp1817420","article-title":"\u201cIs it safe?\u201d\u2014the many unanswered questions about medications and breast-feeding","volume":"380","author":"Byrne","year":"2019","journal-title":"N Engl J Med"},{"key":"R17-20261111","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1111\/bcp.14538","article-title":"Infant drug exposure via breast milk","volume":"88","author":"Verstegen","year":"2022","journal-title":"Br J Clin Pharmacol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:00:13Z","timestamp":1794430813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006153","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]},"assertion":[{"value":"2025-09-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}